Supporting Dewpoint’s novel condensate modulating approach to drug previously ‘undruggable’ therapeutic targets, guided by ...
The collaboration is another vote of confidence in Dewpoint’s biomolecular condensates research, which had already attracted ...
As part of the deal, Dewpoint can expect an undisclosed upfront payment from Mitsubishi Tanabe Pharma Corporation (MTPC) in ...
Privately-held Dewpoint Therapeutics, a Boston, USA, biotech developing therapeutics by targeting biomolecular condensates, ...
Mitsubishi Tanabe Pharma is offering Dewpoint Therapeutics up to $480 million biobucks in a new research pact centering ...
Dewpoint Therapeutics Inc. and Mitsubishi Tanabe Pharma Corp. have entered a research collaboration worth up to $480 million ...
Under the terms of the agreement, Dewpoint will receive an upfront payment and will be eligible for milestone payments based on specified near-term research and development objectives, with a total ...
BEHIND THE FRONT Behind yesterday’s cold front, high pressure is building into the area, yielding drier air. UP AND DOWN ...
Biotechnology company Dewpoint Therapeutics is translating condensate science into breakthrough medicine for diseases with high unmet need. Dewpoint has built an artificial intelligence (AI ...